# Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

> **NCT03173560** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 343 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** lenvatinib
- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT03173560
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2020-02-14
- **Final completion:** 2024-06-20
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2025-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173560, "Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03173560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*